Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for the UK to lead in life sciences and explains why the country has potential as a test bed for medicine launches.
In the end, no matter what political commentators or economists say, the UK will remain a top six or five economy globally, and in any scenario, it will also remain a top ten pharmaceutical market globally
